Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD20 CAR-T Cells in Refractory/Relapsed B-Cell Lymphoma
NCT03576807Phase 1Unknown
- Start
- Apr 2018
- Primary completion
- Apr 2019
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD20 CAR-T cells in B cell lymphoma. Primary endpoint: Study related adverse events at 4 weeks. Status: unknown.
02
Drugs
CD20 CAR-T cells
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT03576807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03576807.